These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31829521)

  • 1. Sequential parallel comparison design with two coprimary endpoints.
    Homma G; Daimon T
    Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential parallel comparison design for "gold standard" noninferiority trials with a prespecified margin.
    Homma G; Daimon T
    Biom J; 2019 Nov; 61(6):1493-1506. PubMed ID: 31456230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes.
    Homma G; Daimon T
    Pharm Stat; 2019 Mar; 18(2):184-197. PubMed ID: 30411482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose finding with the sequential parallel comparison design.
    Wang JJ; Ivanova A
    J Biopharm Stat; 2014; 24(5):1091-101. PubMed ID: 24919070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can sequential parallel comparison design and two-way enriched design be useful in medical device clinical trials?
    Ivanova A; Zhang Z; Thompson L; Yang Y; Kotz RM; Fang X
    J Biopharm Stat; 2016; 26(1):167-77. PubMed ID: 26368863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential parallel comparison design with binary and time-to-event outcomes.
    Silverman RK; Ivanova A; Fine J
    Stat Med; 2018 Apr; 37(9):1454-1466. PubMed ID: 29462838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
    Ouyang J; Zhang P; Carroll KJ; Lee J; Koch G
    J Biopharm Stat; 2020 Jul; 30(4):593-606. PubMed ID: 31829826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimality, sample size, and power calculations for the sequential parallel comparison design.
    Ivanova A; Qaqish B; Schoenfeld DA
    Stat Med; 2011 Oct; 30(23):2793-803. PubMed ID: 21805484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design.
    Silverman RK; Ivanova A
    J Biopharm Stat; 2017; 27(3):416-425. PubMed ID: 28166457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
    Doros G; Pencina M; Rybin D; Meisner A; Fava M
    Stat Med; 2013 Jul; 32(16):2767-89. PubMed ID: 23355369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E; Tango T
    J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo non-response measure in sequential parallel comparison design studies.
    Rybin D; Doros G; Pencina MJ; Fava M
    Stat Med; 2015 Jul; 34(15):2281-93. PubMed ID: 25865181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.